Rush University Medical Center

US Medical Innovations Secures FDA Clearance for Canady Helios Cold Plasma™ Ablation System

Retrieved on: 
星期二, 五月 7, 2024
Research, Robotics, Oncology, Medical Devices, Technology, Artificial Intelligence, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Risk, Innovation system, Doctor of Philosophy, SMC, RNS, Sheba Medical Center, Medicine, RMC, Oncology nursing, Purdue University, Canady, ROS, Surgical oncology, Entrepreneurship, Plasma, Johns Hopkins University, Patient, Multi, Argon, Safety, George Washington University, Microsoft Access, Cell death, Survival, IDE, University of Massachusetts, Treatment, Multimedia, Reactive nitrogen species, Engineer, CHCP, University, Apoptosis, FACS, Field line, Airline, Rush University Medical Center, Reactive oxygen species, Nursing

US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.

Key Points: 
  • US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.
  • The CHCP system consists of the Canady Helios Cold Plasma XL-1000 CP Smart Electrosurgical Generator, Canady Helios Cold Plasma Ablators, Foot Pedal and Trolley Cart.
  • The Canady Helios Cold Plasma™ System introduces a novel approach to soft tissue ablation using plasma.
  • For more information on US Medical Innovation’s products and technology please visit: www.usmedinnovations.com .

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Retrieved on: 
星期五, 五月 3, 2024
FDA, Mayo Clinic, Safety, Food, American Urological Association, Urinary bladder, Carcinoma, Immunotherapy, Hematuria, Abstract, BCG, CIS, Patient, Face, NMIBC, AUA, Urination, Rush University Medical Center, Death, Clinical trial, Annual general meeting, Quality of life, Pharmaceutical industry

IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 2024. These data were featured today at the Paradigm-Shifting, Practice-Changing Clinical Trials in Urology Plenary Session as an oral presentation (Abstract #24-11358) by Dr. Mark D. Tyson, Urologic Oncologist at Mayo Clinic, at the 2024 American Urological Association (AUA) Annual Meeting, in San Antonio, TX. In addition, cretostimogene has shown durable responses over time with twenty-nine patients maintaining a complete response for 12 months or more, pending evaluation and assessment of ongoing responses in twenty-two patients as of the data cutoff. Median duration of response (DOR) was not reached. 92.4% cystectomy-free survival was observed and none of the patients with a complete response had undergone radical cystectomy or showed nodal or metastatic progression.

Key Points: 
  • 92.4% cystectomy-free survival was observed and none of the patients with a complete response had undergone radical cystectomy or showed nodal or metastatic progression.
  • “The positive 12-month BOND-003 data presented at AUA 2024, with a notable duration of response, reinforces cretostimogene monotherapy as a potential backbone therapy in the NMIBC treatment landscape for BCG-unresponsive patients.
  • “Cretostimogene reported remarkable interim efficacy results, with over half of the patients experiencing complete responses upon repeat induction.
  • A webcast replay will be available in the investor relations section on the company's website following the completion of the call.

The Stork Foundation for Infertility Announces Annual "Brunch for Hope" Event in Chicago to Kick-Off National Infertility Awareness Week

Retrieved on: 
星期四, 四月 11, 2024
Education, Jenn Grinels, M.D, Morgan Stanley, REI, Fertility, VIP, Parent, Obstetrics, IVF, Gynaecology, Rush University Medical Center, FACOG, Birth control

CHICAGO, April 11, 2024 /PRNewswire/ -- The Stork Foundation for Infertility, a non-profit offering financial aid to those facing infertility challenges with limited resources; is delighted to announce its second annual Brunch for Hope. The event is scheduled for Sunday, April 21, at Revel Motor Row. Serving as the kickoff for National Infertility Awareness Week, the brunch helps bring supporters together to raise funds and promote awareness for the infertility community.

Key Points: 
  • Serving as the kickoff for National Infertility Awareness Week, the brunch helps bring supporters together to raise funds and promote awareness for the infertility community.
  • Through the supportive community, and those impacted by infertility this event continues to serve as a place to cultivate awareness and equitable support."
  • "We are delighted to start off National Infertility Awareness Week with great passion, launching our second annual Brunch for Hope to honor the resilience of infertility warriors.
  • "At the Stork Foundation, we recognize and understand that infertility transcends mere medical challenges; it portrays a struggle for a treasured dream.

Pathway to Cures Announces First Entrepreneur in Residence

Retrieved on: 
星期一, 三月 11, 2024
Other Philanthropy, Biotechnology, Pharmaceutical, Health, Philanthropy, Fund Raising, Foundation, Other Health, Disease, Coagulopathy, Sickle cell disease, Heredity, Spark Therapeutics, Rush University Medical Center, Entrepreneur in residence, Knowledge, Mortality, Baxalta, EIR, Doctor of Philosophy, MD, MBA, Therapy, Anemia, Blood

Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.

Key Points: 
  • Pathway to Cures (P2C) announced today its first Entrepreneur in Residence (EIR), Leonard Valentino, M.D.
  • Dr. Valentino most recently served as President and CEO of the National Bleeding Disorders Foundation (NBDF) and was instrumental in bringing Pathway to Cures into reality.
  • Pathway to Cures is the venture philanthropy fund of the NBDF focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • “My role as Entrepreneur in Residence for Pathway to Cures will be to provide guidance into the consideration and support of new opportunities for catalyzing transformative therapies and cures.

The Angelman Syndrome Foundation (ASF) and Cedars-Sinai Guerin Children's team up to launch new clinic for families living with Angelman syndrome

Retrieved on: 
星期二, 二月 20, 2024
Social work, Angelman syndrome, Diet, Physician, Rush University Medical Center, Prader–Willi syndrome, Hope, Common, Occupational therapy, Cedars-Sinai Medical Center, Genetics, DSM-IV codes, Walking, Patient, MPH, Speech, Spectrum, Cerebral palsy, UBE3A, Neurology, Gastroenterology, Seizure, Pharmaceutical industry

AURORA, Ill., Feb. 20, 2024 /PRNewswire-PRWeb/ -- The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.

Key Points: 
  • The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.
  • AURORA, Ill., Feb. 20, 2024 /PRNewswire-PRWeb/ -- The Angelman Syndrome Foundation is proud to announce a new collaboration with Cedars-Sinai Guerin Children's to launch a new clinic for patients with Angelman syndrome, a rare neuro-genetic disorder.
  • The clinic is led by Cesar Ochoa-Lubinoff, MD, MPH , director of Developmental-Behavioral Pediatrics at Cedars-Sinai Guerin Children's, who previously co-directed the Angelman syndrome clinic at Rush University Medical Center in Chicago.
  • "In my experience, families facing Angelman syndrome are resilient, but they need a supportive medical team in place," Ochoa-Lubinoff said.

OCCUPATIONAL HEALTH PHYSICIAN URGES CHICAGOANS TO WEAR MASKS/GET VACCINATED

Retrieved on: 
星期五, 二月 16, 2024
Hospital, N95, Workplace, Molina Healthcare, Medical director, SAP, Rush University Medical Center, Public health, Safety, MRO, COVID-19, Virus, Patient, CDC, Water, Nursing

"The latest variant, JN.1, is highly contagious and is driving transmissions, but the newest booster is helping to prevent the spread," Dr. Fletcher says.  "Yet only 20 percent of adults have received the latest vaccine.  It's important to get vaccinated -- especially high-risk patients who have underlying health conditions or are immunosuppressed."

Key Points: 
  • , public health specialist and CEO of SafeWorks Illinois , advises individuals and companies to take measures to prevent the spread of viruses and bacterial-related illnesses over the winter months.
    "
  • The latest variant, JN.1, is highly contagious and is driving transmissions, but the newest booster is helping to prevent the spread," Dr. Fletcher says.  "
  • It's important to get vaccinated -- especially high-risk patients who have underlying health conditions or are immunosuppressed."
  • SafeWorks Illinois offers worker's compensation, occupational health services and corporate programs to create safe, drug-free businesses and industries.

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs

Retrieved on: 
星期四, 二月 15, 2024
NINDS, Central nervous system, Rush University Medical Center, Giant axonal neuropathy, GM2, Rett syndrome, CNS, IP, GAN, IND, AAV, DSM-IV codes, Pharmaceutical industry

DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.

Key Points: 
  • DALLAS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha” or “the Company”), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today provided an update on its deprioritized pipeline programs as part of an ongoing effort to help support their further potential development.
  • Taysha has been working to find ways to advance its deprioritized programs.
  • On November 13, 2023, Taysha terminated its existing loan and security agreement and entered into a new loan and security agreement that provides consent to allow the Company to transfer intellectual property (IP) for several deprioritized programs to third parties in a more efficient manner.
  • “Today’s announcement demonstrates meaningful progress to advance important development work for several deprioritized programs.

Joshua J. Jacobs, MD, FAAOS, Receives American Academy of Orthopaedic Surgeons' Highest Leadership Honor

Retrieved on: 
星期三, 二月 14, 2024
Bangladesh Technical Education Board, SAN, Rush University Medical Center, Research, National Institutes of Health, RUSH, NIH, Rush University, Female, Orthopaedic Research Society, Orthopedic surgery, Life, Learning, Faculty, Mentorship, Rush Medical College, Patient, Health equity, Biology, AAOS, American Academy, Management

The Tipton Leadership Award recognizes AAOS members who have demonstrated outstanding leadership qualities that have benefitted the orthopaedic community, patients and/or the American public.

Key Points: 
  • The Tipton Leadership Award recognizes AAOS members who have demonstrated outstanding leadership qualities that have benefitted the orthopaedic community, patients and/or the American public.
  • "It is a distinctive honor to receive this award.
  • I had the great fortune of working with Dr. Tipton early in my career, when I was 'learning the ropes' of AAOS volunteer service," Dr. Jacobs said.
  • "He was an inspirational leader, who had the ability to evoke the best qualities in people, motivating service for a higher cause."

Molina Healthcare of Illinois Expands Provider Network to Include Rush University System for Health

Retrieved on: 
星期一, 二月 12, 2024
Hospitals, General Health, Health, Other Health, Hospital, Physician, Rush Copley Medical Center, Riverside Medical Center, Rush University Medical Center, Health care, Patient, Medicaid, Molina Healthcare, MMP, Marketplace, Partnership, Nursing

Molina Healthcare of Illinois (“Molina”) announced Rush University System for Health (“Rush”) is now offered as a provider for its Medicaid, Marketplace, and MMP members in the Chicagoland area.

Key Points: 
  • Molina Healthcare of Illinois (“Molina”) announced Rush University System for Health (“Rush”) is now offered as a provider for its Medicaid, Marketplace, and MMP members in the Chicagoland area.
  • “Molina is pleased to offer members greater access to top providers like Rush,” said Matt Wolf, plan president for Molina Healthcare of Illinois.
  • “Molina will be working closely with Rush as our members begin visiting its hospitals and physicians to access the latest technology, resources, and health care.”
    Molina members have access to all four Rush hospitals including Rush University Medical Center, Rush Copley Medical Center, Rush Oak Park Hospital, and Riverside Medical Center.
  • “This new partnership will create greater access to the very best health care for more patients across the Chicago area and Northwest Indiana,” said Lisa Wagamon, president of Rush Health.

Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome

Retrieved on: 
星期三, 一月 10, 2024
Ageing, Patient, CTA, MHRA, Medication, Principal, MECP2, Health care, Rush University Medical Center, AAV, Female, Rett syndrome, European Commission, Orphan drug, Risk, Mutation, Disease, Safety, Central nervous system, Caregiver, Fast Track, FDA, Index, Neurology, Adolescence, MTD, CNS, Pharmaceutical industry

DALLAS, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that the first pediatric patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 pediatric trial in the United States (U.S.) evaluating the safety and preliminary efficacy of TSHA-102 in stage three female patients 5-8 years of age with Rett syndrome. The Company also announced the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Clinical Trial Application (CTA) for TSHA-102 in pediatric patients, enabling expansion of the ongoing U.S. REVEAL pediatric trial into the U.K.

Key Points: 
  • Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-102 to female patients 5-8 years old with stage three Rett syndrome
    MHRA authorized the CTA for TSHA-102 in pediatric patients with Rett syndrome, enabling expansion of ongoing U.S.
  • “Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome.
  • “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease.
  • TSHA-102 is also being evaluated in the ongoing first-in-human REVEAL Phase 1/2 adolescent and adult trial in females aged 12 and older with Rett syndrome in Canada.